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S U M M A R Y
In January 2015, there was an outbreak of avian-origin inﬂuenza A (H7N9) virus in Zhejiang Province,
China. A 45-year-old man was admitted to the First Afﬁliated Hospital of Zhejiang University with a high
fever that had lasted 7 days, chills, and a cough with yellow sputum. Laboratory testing conﬁrmed
infection with the H7N9 virus, likely obtained from contact with poultry at a local live poultry market. A
large dense shadow was apparent in the patient’s left lung at the time of admission. Treatment with
oseltamivir (75 mg twice daily) did not improve the patient’s condition. The decision was made to try
using convalescent plasma to treat the infection. Convalescent plasma was administered 3 days after the
patient was admitted to the hospital and led to a marked improvement. To our knowledge, this is the ﬁrst
report of the successful use of convalescent plasma to treat a case of H7N9 infection in China. These
results suggest that the combination of convalescent plasma and antiviral drugs may be effective for the
treatment of avian-origin H7N9 infection.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Avian-origin inﬂuenza A (H7N9) infections have been reported
for the past 2 years, but the mortality rate remains unacceptably
high (52%). In January 2015, A 45-year-old patient infected with
H7N9 have recovered after using convalescent plasma. It is the ﬁrst
report of the successful use of convalescent plasma to treat a case
of H7N9 infection in China.
2. Case report
A previously healthy 45-year-old man was admitted to the First
Afﬁliated Hospital of Zhejiang University on January 16, 2015. He
had a high fever (39 8C) that had lasted for 7 days, chills, and a
cough with yellow sputum. The patient had been in contact with
live birds at a local live poultry market (January 1, 2015), but had
not had contact with inﬂuenza patients. On January 9, he had
developed a high fever and chills. Four days later he reported being
short of breath, and on January 15 he had relatively severe
hypoxemia. The patient’s oxygen saturation levels fell to less than* Corresponding author. Tel.: +86 13906514210; fax: +86 057187236459.
E-mail address: ljli@zju.edu.cn (L.-J. Li).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).80% (mask measurement) and the arterial blood oxygen partial
pressure fell to less than 50%. Non-invasive ventilator-assisted
breathing was administered upon his admission to the hospital. A
chest radiograph performed the day he was admitted showed a
large dense shadow in the left lung with a blurred edge; the right
lung was clear (Fig. 1A). Deep sputum was collected through a
sputum suction tube and sent to the hospital laboratory for
analysis. The inﬂuenza A (H7N9) virus was detected by reverse
transcriptase PCR (RT-PCR) assay.
Routine blood tests found a normal number of leukocytes;
however, the percentage of neutrophils was elevated (87.9%). The
number of lymphocytes was also decreased to 0.4  109 cells/l.
Routine blood tests were performed every day. Liver function tests
indicated elevated alanine aminotransferase (73 U/l) and aspartate
aminotransferase (144 U/l) levels. The patient’s total cholesterol
was normal. Renal function, electrolyte, and blood coagulation
tests showed no obvious abnormalities. Arterial blood gas tests
detected no obvious abnormalities after intubation. C-reactive
protein and procalcitonin were monitored until January 28
(Supplementary Material, Figure S1).
The patient was admitted to the negative-pressure ward, which
is a specialized intensive care unit for treating infectious diseases.
He was monitored by electrocardiograph. Nutrition was supplied
through a jejunum tube. Treatment with 75 mg of oseltamivirciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. X-ray and computed tomography scans of the chest of a 45-year-old man with pneumonia caused by avian-origin inﬂuenza A (H7N9) virus. (A) X-ray image obtained
at the time of hospital admission (January 16, 2015). A large dense shadow with blurred edges was observed in the left lung. The right lung was clear. (B) X-ray image obtained
on January 17 after treatment with oseltamivir. No improvement was noted from admission. (C) X-ray image obtained on January 19 prior to treatment with convalescent
plasma. The large dense shadow noted at admission was still apparent. (D) Computed tomography scan obtained on February 2 at the time of discharge. The dense shadow in
the left lung had clearly been absorbed.
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Preventive piperacillin (0.5625 g every 6 h) and tazobactam
(0.5625 g every 6 h) were administered from January 16 to January
26. The patient’s temperature was recorded daily (Supplementary
Material, Figure S2). Cultures were performed on samples from the
blood, sputum, feces, and catheter drainage. All of the tests were
negative, with the exception of the sputum culture on January 27,
2015, in which a small amount of smoke Aspergillus was detected.
The patient was treated with trazodone for 3 days, and the sputum
culture was negative after treatment.
Despite the continuous use of oseltamivir, virus was detected in
the sputum specimens by the laboratory. Chest radiographs
obtained on January 17 (Fig. 1B) and January 19 (Fig. 1C) showed
no improvement from the time of admission. From January 16 until
January 19 the patient showed no improvement in his condition,
and appeared to be worsening. While he was hospitalized, the
patient also received probiotics, human blood albumin, immuno-
globulin, methyl prednisolone, acetylcysteine, compound glycyr-
rhizin, and reduced glutathione. The H7N9 virus in this patient was
not obviously resistant to oseltamivir, but there had been a report
of oseltamivir resistance in another case.1 We did not attempt to
administer oseltamivir 150 mg twice daily or peramivir to thispatient, and zanamivir is rarely used in our hospital. The
suggestion was made that convalescent plasma could be used to
treat the patient and this option was favored by the patient’s family
members.
A woman from Zhejiang Province who had recovered from
H7N9 infection in April 2014 donated her convalescent plasma.
The plasma was collected by apheresis at the Blood Center of
Zhejiang Province (200 ml total) and contained a neutralizing
antibody titer of 1:80. The convalescent plasma was conﬁrmed free
of infectious agents and was stored at 40 8C until it could be used.
The 200 ml of convalescent plasma was given to the patient over a
period of 3 h beginning at 2 p.m. on January 19 (Supplementary
Material, Figure S3). Laboratory results indicated that the H7N9
virus was undetectable on January 23. Oseltamivir was stopped on
January 24 after the RT-PCR assay consistently failed to detect the
H7N9 virus in the sputum specimens.
During patient follow-up in the hospital, the patient’s liver
function improved. Likewise, routine blood tests showed that
the number of lymphocytes had normalized on January 23 and
the proportion of neutrophils normalized on January 30. The
patient’s condition improved gradually and the endotracheal
tube was removed on January 27. A computed tomography scan
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left lung had improved markedly from January 19 (Fig. 1D). The
patient recovered and was discharged on February 2, 2015.
The inﬂuenza A (H7N9) virus was isolated successfully from
tracheal aspirates obtained from the plasma donor and the patient.
The neutralizing antibody titer against the virus was assessed in
samples from the patient in a biosafety level 3 laboratory. A
hemagglutinin inhibition (HAI) assay was performed simultaneous-
ly. The HAI titer exceeded 1:512. Neutralizing antibodies were not
detectable on January 19, but increased steadily. At discharge, the
patient had a neutralizing antibody titer greater than 1:80. The
increase is likely attributable to the treatment with convalescent
plasma and the patient’s own humoral immune response.
3. Discussion
Avian-origin inﬂuenza A (H7N9) infections have been reported
for the past 2 years. In the absence of an effective treatment, the
mortality rate remains unacceptably high (52%). Convalescent
plasma has been used successfully to treat Spanish inﬂuenza,
inﬂuenza A (H5N1), and severe pandemic inﬂuenza A (H1N1)
2009.2–4 However, to our knowledge this is the ﬁrst case in which
convalescent plasma has been used successfully to treat an avian
inﬂuenza A (H7N9) infection in China. These results suggest that
convalescent plasma combined with antiviral drugs may be a
viable option for the treatment of H7N9 infection. These ﬁndings
remain to be conﬁrmed in a prospective cohort study.Acknowledgements
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Supplementary data associated with this article can be found, in
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